NOT KNOWN FACTUAL STATEMENTS ABOUT ETOPOSIDE

Treatment method with SR18662 considerably lessens expansion and proliferation of CRC cells. SR18662 shows enhanced efficacy in decreasing viability of many CRC cell strains. Movement cytometry Assessment pursuing SR18662 therapy demonstrates an increase in cells captured in both S or G2/M phases on the mobile cycle and a big boost in the amount of